Overview
InspireMD Q3 revenue grows 39% yr/yr, beating analyst expectations
Net income for Q3 beats analyst estimates despite larger net loss
Company attributes revenue growth to U.S. launch and international market penetration
Outlook
InspireMD highlights strong demand for its CGuard Prime globally
Company emphasizes strategic focus on U.S. commercial expansion
InspireMD strengthens financial position with $58 mln in gross proceeds
Result Drivers
U.S. LAUNCH - Successful U.S. commercial launch of CGuard Prime carotid stent system contributed significantly to revenue growth
INTERNATIONAL PENETRATION - Increased penetration in international markets boosted revenue
OPERATING EXPENSES - Rise in operating expenses due to U.S. personnel expansion and establishment of U.S. headquarters
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $2.52 mln | $1.76 mln (2 Analysts) |
Q3 Net Income | Beat | -$12.71 mln | -$14.60 mln (2 Analysts) |
Q3 Income From Operations | Beat | -$13.05 mln | -$14.60 mln (2 Analysts) |
Q3 Basic EPS | -$0.17 | ||
Q3 Gross Profit | $864,000 | ||
Q3 Operating Expenses | $13.91 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for InspireMD Inc is $4.50, about 49.1% above its November 3 closing price of $2.29
Press Release: ID:nGNX9JHY2S
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)